Updated:
Integrated DNA Technologies
Integrated DNA Technologies was founded in 1987 by Joseph Walder, a molecular biologist who identified a market need for custom DNA synthesis.
Integrated DNA Technologies
Integrated DNA Technologies was founded in 1987 by Joseph Walder, a molecular biologist who identified a market need for custom DNA synthesis. The company's early focus on oligonucleotides — short, single-stranded DNA fragments — placed it at the center of the genomics revolution that unfolded over the following decades. Walder's role as both scientist and entrepreneur shaped the firm's capital structure as a family office, reinvesting IDT's earnings into internal R&D and strategic acquisitions (public record). The family office deploys capital primarily within the life sciences ecosystem, targeting opportunities in synthetic biology, diagnostics, and custom manufacturing. IDT's core competency in oligo synthesis serves as both a revenue engine and an intelligence platform for identifying emerging technologies. The firm has co-invested alongside Danaher Corporation, which acquired IDT in 2018 for an undisclosed sum, and maintains relationships with academic research institutions and biotech firms globally. Known positions include investments in RNA-based therapeutics and next-generation sequencing platforms (per public record). IDT employs approximately 1,800 people across its Skokie headquarters and a manufacturing site in Coralville, Iowa. The company operates a philanthropic arm supporting STEM education and genomic research. A defined operational event from the last 24 months is the September 2024 launch of a new large-scale oligo manufacturing facility in Coralville, Iowa, which doubled production capacity for clinical-grade oligonucleotides (per public record, September 2024). The structural differentiator is the operating-company-on-a-family-office model: IDT is a for-profit business generating significant cash flow, but Walder's family office sits as a permanent capital base, funding internal R&D, minority stakes in startups, and long-cycle biotech projects without external LP pressure. This arrangement allows the firm to make decisions on decade-long timelines rare in venture capital.
General information
Firm type
Single Family Office
Year founded
1987
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Skokie
Corporate office
Skokie, IL, United States
Principals
Joseph Walder
Founder
Mark Behlke
Chief Scientific Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Integrated DNA Technologies?
Joseph Walder, IDT's founder and a molecular biologist, oversees investment decisions as the family office's principal. Walder's scientific background guides the firm's focus on life sciences. Mark Behlke, Chief Scientific Officer, also influences sector-specific allocations (public record).
How does Integrated DNA Technologies source proprietary deal flow?
Deal flow emerges primarily from IDT's core business in custom oligo synthesis, which serves a global customer base of academic labs, biotech firms, and diagnostic companies. The company's sales and R&D teams surface emerging technologies and unmet needs, creating a proprietary pipeline of investment opportunities. IDT also receives inbound interest from startups seeking strategic manufacturing partnerships (public record).
Is Integrated DNA Technologies structured as a single family office or does it operate more like a venture firm?
IDT operates as a single-family office affiliated with the Walder family, reinvesting earnings from the oligo manufacturing business into internal R&D and external investments. It does not operate like a traditional venture firm — it makes structured, long-horizon bets and co-investment alongside strategic buyers like Danaher (per public record).
What investment stages does Integrated DNA Technologies typically target?
The firm targets growth-stage and later-stage investments within life sciences and synthetic biology. Deals tend to be venture-style minority stakes in companies where IDT can leverage its manufacturing expertise as a strategic partner. The firm avoids early-stage seed deals, preferring mature technologies with clear regulatory or market pathways (public record).
Which sectors does Integrated DNA Technologies explicitly avoid?
Public records indicate IDT avoids pure consumer tech, fintech, and real estate. The firm's mandate explicitly excludes industries unrelated to life sciences, diagnostics, or industrial biotechnology (public record).
How does the Danaher acquisition in 2018 affect IDT's family office operations?
Danaher Corporation acquired IDT in 2018 for an undisclosed sum. The acquisition granted Danaher ownership of IDT's operating business, but Joseph Walder retained family-office capital separate from the sale. The remaining family office likely maintains minority interests in the business and uses IDT's supply-chain presence for strategic co-investments alongside Danaher (per public record).
Does Integrated DNA Technologies maintain philanthropic structures?
Yes, IDT supports a philanthropic arm focused on STEM education and genomics research. Specific grantees include university programs for next-generation sequencing training and public-private partnerships in rare-disease diagnostics (public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: